Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Acta Neurologica Scandinavica

• Publication date

  1990-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1600-0404.1990.tb00926.xPMID 2330812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of racemic (+) and (-) N-[methyl-11C]nomifensine, a ligand for evaluation of monoamine re-uptake sites by use of positron emission tomography.

  1989cited by this paper
• Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers.

  1988cited by this paper
• Receptor binding and selectivity of three 11C‐labelled dopamine receptor antagonists in the brain of Rhesus monkeys studied with positron emission tomography

  1988cited by this paper
• [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics.

  1988cited by this paper
• Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease

  1988cited by this paper
• Metabolites of 6-[18F]fluoro-L-dopa in human blood.

  1988cited by this paper
• Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone

  1987cited by this paper
• In vivo evaluation of striatal dopamine reuptake sites using 11C‐nomifensine and positron emission tomography

  1987cited by this paper
• Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using 11C‐N‐methyl‐spiperone

  1987cited by this paper
• Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate

  1987cited by this paper
• Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET).

  1987cited by this paper
• Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.

  1987cited by this paper
• Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects.

  1986cited by this paper
• Autoradiographic Visualization and Quantification of Dopamine Receptors and Uptake Sites in the Rat and Human CNS

  1986cited by this paper
• Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

  1986cited by this paper
• Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands

  1986cited by this paper
• Metabolism of nomifensine after oral and intravenous administration

  1986cited by this paper
• Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography

  1986cited by this paper
• [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine.

  1986cited by this paper
• Recent Developments in Parkinson's Disease

  1986cited by this paper
• High yield synthesis of 6-[18F]fluoro-L-dopa.

  1986cited by this paper
• Inhibition of L‐{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography

  1986cited by this paper
• Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

  1986cited by this paper
• Striatal dopamine distribution in parkinsonian patients during life.

  1985cited by this paper
• Quantitative autoradiography of 3H-nomifensine binding sites in rat brain.

  1985cited by this paper
• Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes.

  1985cited by this paper
• Kinetics and metabolism of nomifensine.

  1984cited by this paper
• Performance Study of the PC‐384 Positron Camera System for Emission Tomography of the Brain

  1984cited by this paper
• Stereoselective inhibition of synaptosomal catecholamine uptake by nomifensine.

  1984cited by this paper
• Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography

  1984cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper
• Dopamine visualized in the basal ganglia of living man

  1983cited by this paper
• Dopaminergic Deficiency is More Pronounced in Putamen than in Nucleus Caudatus in Parkinson's Disease

  1983cited by this paper
• Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects

  1981cited by this paper
• Aromatic L‐amino acid decarboxylase in rat corpus striatum

  1981cited by this paper
• Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonism

  1980cited by this paper
• [18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine.

  1978cited by this paper
• Further aspects of nomifensine pharmacology.

  1977cited by this paper
• Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.

  1977cited by this paper
• Pharmacokinetic interpretation of steady state concentration of antipyrine and other drugs in plasma.

  1977cited by this paper
• THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1

  1977cited by this paper
• The neurochemistry of Parkinson's disease: effect of L-dopa therapy.

  1975cited by this paper
• 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

  1975cited by this paper
• 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

  1975cited by this paper
• Rat brain regional uptake and decarboxylation of L-DOPA following carotid injection.

  1975cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions

  1970cited by this paper

• Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson

  2023cites this paper
• Positron Emission Tomography of the

  2020cites this paper
• Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside

  2017cites this paper
• An Overview of PET Studies of the Cerebral Uptake of Amino Acids

  2015cites this paper
• The Human Experience with Intravenous Levodopa

  2015cites this paper
• Positron emission tomography imaging in neurological disorders

  2012cites this paper
• Positron emission tomography neuroimaging in Parkinson's disease.

  2011cites this paper
• In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia.

  2009cites this paper
• Evidence for plasticity of the dopaminergic system in Parkinsonism

  2008cites this paper
• Radiopharmaceuticals: molecular imaging using positron emission tomography.

  2008cites this paper
• Manganese induced brain lesions inMacaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging

  2005cites this paper
• Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey

  2005cites this paper
• Where have we got to with neuroreceptor mapping of the human brain?

  2004cites this paper
• Functional brain imaging in the differential diagnosis of Parkinson's disease.

  2004cites this paper
• [PET in neurology and psychiatry. II].

  2002cites this paper
• PET en neurología y psiquiatría II

  2002cites this paper
• The effect of aromatic fluorine substitution in l-DOPA on the in vivo behaviour of [18F]2-, [18F]5- and [18F]6-fluoro-l-DOPA in the human brain☆

  2002cites this paper
• Interaction of a Muscarinic Cholinergic Agonist on Acetylcholine and Dopamine Receptors in the Monkey Brain Studied with Positron Emission Tomography

  2002cites this paper
• FDOPA metabolism in the adult porcine brain: influence of tracer circulation time and VOI selection on estimates of striatal DOPA decarboxylation.

  2001cites this paper
• Increased pineal Fdopa uptake is related to severity of Parkinson's disease – A PET study

  2001cites this paper
• [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.

  2001cites this paper
• Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus.

  2001cites this paper
• Functional Imaging in Parkinson's Disease

  2001cites this paper
• [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease

  2001cites this paper
• The effects of surgical treatment of Parkinson's disease on brain function: PET findings.

  2000cites this paper
• Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease

  2000cites this paper
• Localization of trapping of 6‐[18F]fluoro‐L‐m‐tyrosine, an aromatic L‐amino acid decarboxylase tracer for PET

  1999cites this paper
• Striatal uptake of a novel PET ligand, [18F]β‐CFT, is reduced in early Parkinson's disease

  1999cites this paper
• NMDA‐Receptor Activity Visualized with (S)‐[N‐Methyl‐11C]Ketamine and Positron Emission Tomography in Patients with Medial Temporal Lobe Epilepsy

  1999cites this paper
• Positron emission tomography studies in movement disorders.

  1998cites this paper
• Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms

  1998cites this paper
• The early diagnosis of parkinson's disease

  1998cites this paper
• On the Rate of Decarboxylation of Dopa to Dopamine in Living Mammalian Brain a

  1997cites this paper
• Positron emission tomography studies of healthy volunteers-no effects on the dopamine terminals and synthesis after short term exposure to toluene

  1997cites this paper
• Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

  1997cites this paper
• PET and SPECT studies in Parkinson's disease.

  1997cites this paper
• The labelling of a novel tropane derivative [11C]NS 2214 (BMS-204756) - An inhibitor of the dopamine transporter

  1997cites this paper
• Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography.

  1997cites this paper
• Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey.

  1997cites this paper
• Biological imaging and the molecular basis of dopaminergic diseases.

  1997cites this paper
• Immunochemical analysis of dopamine transporter protein in Parkinson's disease

  1997cites this paper
• Advances in imaging Parkinson's disease.

  1997cites this paper
• Functional effects of striatal dysfunction in Parkinson disease.

  1997cites this paper
• Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study

  1997cites this paper
• Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects

  1997cites this paper
• Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.

  1996cites this paper
• Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration.

  1996cites this paper
• Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease.

  1996cites this paper
• Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography.

  1996cites this paper
• Neuroimaging in Neurological Disorders

  1996cites this paper
• Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.

  1996cites this paper
• Peduncular 'Rubral' Tremor and Dopaminergic Denervation

  1995cites this paper
• Positron Emission Tomography with [11C]Deuterium‐Deprenyl in Temporal Lobe Epilepsy

  1995cites this paper
• Imaging the head: functional imaging.

  1995cites this paper
• Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

  1995cites this paper
• Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease

  1995cites this paper
• Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers

  1995cites this paper
• Nigrofrontal dopaminergic function as assessed by 18F‐dopa PET

  1995cites this paper
• Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.

  1995cites this paper
• PET imaging of neocortical monoaminergic terminals in Parkinson's disease

  1995cites this paper
• Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patients

  1995cites this paper
• [The dopamine transporter: characterization and physiopathologic implications].

  1995cites this paper
• PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.

  1995cites this paper
• PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease

  1995cites this paper
• PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.

  1995cites this paper
• Parkinson's disease--a single clinical entity?

  1995cites this paper
• [Positron-emission tomographic studies of the brain in parkinsonism patients].

  1995cites this paper
• PET studies of the striatal dopaminergic system in Parkinson's disease (PD).

  1995cites this paper
• Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET).

  1994cites this paper
• Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits

  1994cites this paper
• Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

  1994cites this paper
• The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?

  1993cites this paper
• The role of positron emission tomography in the assessment of human neurotransplantation.

  1993cites this paper
• Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices

  1993cites this paper
• Positron emission tomography (PET) study: the effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP, SUN 0588) on the central dopamine D1, D2 and D3 receptors in rhesus monkey.

  1993cites this paper
• Functional imaging in relation to parkinsonian syndromes.

  1993cites this paper
• PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease

  1993cites this paper
• Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.

  1993cites this paper
• Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.

  1992cites this paper
• Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants

  1992cites this paper
• Cerebral uptake and utilization of therapeutic [β‐11C]‐L‐DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response

  1992cites this paper
• Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography

  1992cites this paper
• Isolated tremor and disruption of the nigrostriatal dopaminergic system

  1992cites this paper
• The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred

  1992cites this paper
• PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry.

  1992cites this paper
• Uptake and utilization of [beta-11C]5-hydroxytryptophan in human brain studied by positron emission tomography.

  1992cites this paper
• What has PET told us about Parkinson's disease?

  1991cites this paper
• Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies

  1991cites this paper
• Detection of preclinical Parkinson's disease with PET

  1991cites this paper
• Positron emission tomography studies of brain receptors

  1991cites this paper
• Dopa‐responsive dystonia: [18F]dopa positron emission tomography

  1991cites this paper
• Monoamine Precursors in PET Research- Biochemical Issues and Functional Significance

  1991cites this paper
• Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study

  1991cites this paper
• Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: A positron emission tomographic study

  1991cites this paper
• Obsessional slowness. Functional studies with positron emission tomography.

  1991cites this paper
• Positron emission tomography studies of neurotransmitter systems

  1990cites this paper
• 6‐[18F]Fluoro‐L‐DOPA probes dopamine turnover rates in central dopaminergic structures

  1990cites this paper
• Striatal function in normal aging: Implications for Parkinson's disease

  1990cites this paper
• Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

  1990cites this paper
• PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease

  1990cites this paper